Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal

Proactive - Interviews for investors

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the publication of the company’s Phase 1 and Phase 1b clinical trial results for IMU-856 in The Lancet Gastroenterology & Hepatology. Muehler highlighted the company’s excitement regarding the publication, underscoring how it validates the significance of IMU-856’s clinical data for the medical field. He expressed gratitude to the authors, investigators, and patients involved in this trial, acknowledging their roles in achieving this milestone. The clinical trial’s first stages explored the safety and tolerability of IMU-856, with parts A and B focused on healthy volunteers. Muehler confirmed that the treatment was well tolerated and revealed a favorable pharmacokinetic profile, with a convenient daily oral dosing schedule. He emphasized that this Phase 1 study also ventured into the therapeutic potential for IMU-856 in celiac disease, an under-addressed condition without approved treatments. The trial’s design allowed Immunic to test how IMU-856 might alleviate the effects of gluten on patients, with encouraging results for celiac disease symptom management and nutrient absorption. IMU-856’s distinct mode of action sets it apart from other treatments, as it supports epithelial regeneration in the bowel without targeting the immune system directly. This approach holds promise for enhancing gut health and protecting the bowel’s barrier function. Immunic is exploring additional applications of IMU-856 for other gastrointestinal conditions, aiming to demonstrate its broader therapeutic potential. As Muehler noted, "The bowel barrier function and epithelial architecture are critical for many gastrointestinal diseases, beyond celiac disease." Visit Proactive's YouTube channel for more in-depth conversations, and don’t forget to like the video, subscribe, and enable notifications for future updates. #ImmunicInc #IMU856 #CeliacDisease #ClinicalTrials #GutHealth #Gastroenterology #DrugDevelopment #AutoimmuneDisease #ProactiveInvestors #MedicalResearch #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews